Publications 2022

Hultcrantz M, Rustad EH, Yellapantula V, Jacob A, Akhlaghi T, Korde N, Mailankody S, Lesokhin AM, Hassoun H, Smith EL, Lahoud OB, Landau HJ, Shah GL, Scordo M, Chung DJ, Giralt S, Papaemmanuil E, Landgren O (2022)
Capture Rate of V(D)J Sequencing for Minimal Residual Disease Detection in Multiple Myeloma
Clin Cancer Res, 28 (10), 2160-2166
DOI 10.1158/1078-0432.CCR-20-2995, PubMed 35553646

Misund K, Hofste Op Bruinink D, Coward E, Hoogenboezem RM, Rustad EH, Sanders MA, Rye M, Sponaas AM, van der Holt B, Zweegman S, Hovig E, Meza-Zepeda LA, Sundan A, Myklebost O, Sonneveld P, Waage A (2022)
Clonal evolution after treatment pressure in multiple myeloma: heterogenous genomic aberrations and transcriptomic convergence
Leukemia, 36 (7), 1887-1897
DOI 10.1038/s41375-022-01597-y, PubMed 35643867

Riise J, Meyer S, Blaas I, Chopra A, Tran TT, Delic-Sarac M, Hestdalen ML, Brodin E, Rustad EH, Dai KZ, Vaage JT, Nissen-Meyer LSH, Sund F, Wader KF, Bjornevik AT, Meyer PA, Nygaard GO, König M, Smeland S, Lund-Johansen F, Olweus J, Kolstad A (2022)
Rituximab-treated patients with lymphoma develop strong CD8 T-cell responses following COVID-19 vaccination
Br J Haematol, 197 (6), 697-708
DOI 10.1111/bjh.18149, PubMed 35254660

Publications 2021

Boyle EM, Deshpande S, Tytarenko R, Ashby C, Wang Y, Bauer MA, Johnson SK, Wardell CP, Thanendrarajan S, Zangari M, Facon T, Dumontet C, Barlogie B, Arbini A, Rustad EH, Maura F, Landgren O, Zhan F, van Rhee F, Schinke C, Davies FE, Morgan GJ, Walker BA (2021)
The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
Nat Commun, 12 (1), 293
DOI 10.1038/s41467-020-20524-2, PubMed 33436579

Diamond B, Korde N, Lesokhin AM, Smith EL, Shah U, Mailankody S, Hultcrantz M, Hassoun H, Lu SX, Tan C, Rustad EH, Maura F, Maclachlan K, Peterson T, Derkach A, Devlin S, Landau HJ, Scordo M, Chung DJ, Shah GL, Lahoud O, Thoren K, Murata K, Ramanathan L, Arcila ME et al. (2021)
Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial
Lancet Haematol, 8 (6), e422-e432
DOI 10.1016/S2352-3026(21)00130-7, PubMed 34048681

Diamond B, Yellapantula V, Rustad EH, Maclachlan KH, Mayerhoefer M, Kaiser M, Morgan G, Landgren O, Maura F (2021)
Positive selection as the unifying force for clonal evolution in multiple myeloma
Leukemia, 35 (5), 1511-1515
DOI 10.1038/s41375-021-01130-7, PubMed 33483619

Landau HJ, Yellapantula V, Diamond BT, Rustad EH, Maclachlan KH, Gundem G, Medina-Martinez J, Ossa JA, Levine MF, Zhou Y, Kappagantula R, Baez P, Attiyeh M, Makohon-Moore A, Zhang L, Boyle EM, Ashby C, Blaney P, Patel M, Zhang Y, Dogan A, Chung DJ, Giralt S, Lahoud OB, Peled JU et al. (2021)
Author Correction: Accelerated single cell seeding in relapsed multiple myeloma
Nat Commun, 12 (1), 591
DOI 10.1038/s41467-021-20978-y, PubMed 33473129

Landgren O, Hultcrantz M, Diamond B, Lesokhin AM, Mailankody S, Hassoun H, Tan C, Shah UA, Lu SX, Salcedo M, Werner K, Rispoli J, Caple J, Sams A, Verducci D, Jones K, Concepcion I, Ciardello A, Chansakul A, Schlossman J, Tavitian E, Shekarkhand T, Harrison A, Piacentini C, Rustad EH et al. (2021)
Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma: The MANHATTAN Nonrandomized Clinical Trial
JAMA Oncol, 7 (6), 862-868
DOI 10.1001/jamaoncol.2021.0611, PubMed 33856405

Maclachlan KH, Rustad EH, Derkach A, Zheng-Lin B, Yellapantula V, Diamond B, Hultcrantz M, Ziccheddu B, Boyle EM, Blaney P, Bolli N, Zhang Y, Dogan A, Lesokhin AM, Morgan GJ, Landgren O, Maura F (2021)
Copy number signatures predict chromothripsis and clinical outcomes in newly diagnosed multiple myeloma
Nat Commun, 12 (1), 5172
DOI 10.1038/s41467-021-25469-8, PubMed 34453055

Maura F, Boyle EM, Rustad EH, Ashby C, Kaminetzky D, Bruno B, Braunstein M, Bauer M, Blaney P, Wang Y, Ghamlouch H, Williams L, Stoeckle J, Davies FE, Walker BA, Maclachlan K, Diamond B, Landgren O, Morgan GJ (2021)
Chromothripsis as a pathogenic driver of multiple myeloma
Semin Cell Dev Biol, 123, 115-123
DOI 10.1016/j.semcdb.2021.04.014, PubMed 33958284

Maura F, Diamond B, Maclachlan KH, Derkach A, Yellapantula VD, Rustad EH, Hultcrantz M, Shah UA, Hong J, Landau HJ, Iacobuzio-Donahue CA, Papaemmanuil E, Irby S, Crowley L, Crane M, Webber MP, Goldfarb DG, Zeig-Owens R, Giricz O, Verma A, Prezant DJ, Dogan A, Shah SP, Zhang Y, Landgren O (2021)
Initial Whole-Genome Sequencing of Plasma Cell Neoplasms in First Responders and Recovery Workers Exposed to the World Trade Center Attack of September 11, 2001
Clin Cancer Res, 27 (7), 2111-2118
DOI 10.1158/1078-0432.CCR-20-2245, PubMed 33504553

Rustad EH, Nadeu F, Angelopoulos N, Ziccheddu B, Bolli N, Puente XS, Campo E, Landgren O, Maura F (2021)
mmsig: a fitting approach to accurately identify somatic mutational signatures in hematological malignancies
Commun Biol, 4 (1), 424
DOI 10.1038/s42003-021-01938-0, PubMed 33782531

Publications 2020

D'Agostino M, Zaccaria GM, Ziccheddu B, Rustad EH, Genuardi E, Capra A, Oliva S, Auclair D, Yesil J, Colucci P, Keats JJ, Gambella M, Bringhen S, Larocca A, Boccadoro M, Bolli N, Maura F, Gay F (2020)
Early Relapse Risk in Patients with Newly Diagnosed Multiple Myeloma Characterized by Next-generation Sequencing
Clin Cancer Res, 26 (18), 4832-4841
DOI 10.1158/1078-0432.CCR-20-0951, PubMed 32616499

Diamond BT, Rustad E, Maclachlan K, Thoren K, Ho C, Roshal M, Ulaner GA, Landgren CO (2020)
Defining the undetectable: The current landscape of minimal residual disease assessment in multiple myeloma and goals for future clarity
Blood Rev, 46, 100732
DOI 10.1016/j.blre.2020.100732, PubMed 32771227

Eveillard M, Rustad E, Roshal M, Zhang Y, Ciardiello A, Korde N, Hultcrantz M, Lu S, Shah U, Hassoun H, Smith E, Lesokhin A, Mailankody S, Landgren O, Thoren K (2020)
Comparison of MALDI-TOF mass spectrometry analysis of peripheral blood and bone marrow-based flow cytometry for tracking measurable residual disease in patients with multiple myeloma
Br J Haematol, 189 (5), 904-907
DOI 10.1111/bjh.16443, PubMed 32026474

Ho C, Syed M, Roshal M, Petrova-Drus K, Moung C, Yao J, Quesada AE, Benhamida J, Vanderbilt C, Liu Y, Zhu M, Yu W, Maciag L, Wang M, Ma Y, Gao Q, Rustad EH, Hultcrantz M, Diamond BT, Zheng-Lin B, Huang Y, Hutt K, Miller JE, Dogan A, Nafa K et al. (2020)
Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing: Feasibility, Challenges, and Direct Comparison with High-Sensitivity Flow Cytometry
J Mol Diagn, 23 (2), 181-199
DOI 10.1016/j.jmoldx.2020.10.015, PubMed 33217553

Hultcrantz M, Rustad EH, Yellapantula V, Arcila M, Ho C, Syed MH, Papaemmanuil E, Zhang Y, Maura F, Landgren O (2020)
Baseline VDJ clonotype detection using a targeted sequencing NGS assay: allowing for subsequent MRD assessment
Blood Cancer J, 10 (7), 76
DOI 10.1038/s41408-020-00343-w, PubMed 32699232

Hultcrantz M, Yellapantula V, Rustad EH (2020)
Genomic profiling of multiple myeloma: New insights and modern technologies
Best Pract Res Clin Haematol, 33 (1), 101153
DOI 10.1016/j.beha.2020.101153, PubMed 32139018

Landau HJ, Yellapantula V, Diamond BT, Rustad EH, Maclachlan KH, Gundem G, Medina-Martinez J, Ossa JA, Levine MF, Zhou Y, Kappagantula R, Baez P, Attiyeh M, Makohon-Moore A, Zhang L, Boyle EM, Ashby C, Blaney P, Patel M, Zhang Y, Dogan A, Chung DJ, Giralt S, Lahoud OB, Peled JU et al. (2020)
Accelerated single cell seeding in relapsed multiple myeloma
Nat Commun, 11 (1), 3617
DOI 10.1038/s41467-020-17459-z, PubMed 32680998

Maura F, Bolli N, Rustad EH, Hultcrantz M, Munshi N, Landgren O (2020)
Moving From Cancer Burden to Cancer Genomics for Smoldering Myeloma: A Review
JAMA Oncol, 6 (3), 425-432
DOI 10.1001/jamaoncol.2019.4659, PubMed 31830214

Maura F, Rustad EH, Boyle EM, Morgan GJ (2020)
Reconstructing the evolutionary history of multiple myeloma
Best Pract Res Clin Haematol, 33 (1), 101145
DOI 10.1016/j.beha.2020.101145, PubMed 32139011

Rustad EH, Boyle EM (2020)
Monitoring minimal residual disease in the bone marrow using next generation sequencing
Best Pract Res Clin Haematol, 33 (1), 101149
DOI 10.1016/j.beha.2020.101149, PubMed 32139014

Rustad EH, Yellapantula V, Leongamornlert D, Bolli N, Ledergor G, Nadeu F, Angelopoulos N, Dawson KJ, Mitchell TJ, Osborne RJ, Ziccheddu B, Carniti C, Montefusco V, Corradini P, Anderson KC, Moreau P, Papaemmanuil E, Alexandrov LB, Puente XS, Campo E, Siebert R, Avet-Loiseau H, Landgren O, Munshi N, Campbell PJ et al. (2020)
Timing the initiation of multiple myeloma
Nat Commun, 11 (1), 1917
DOI 10.1038/s41467-020-15740-9, PubMed 32317634

Rustad EH, Yellapantula VD, Glodzik D, Maclachlan KH, Diamond B, Boyle EM, Ashby C, Blaney P, Gundem G, Hultcrantz M, Leongamornlert D, Angelopoulos N, Agnelli L, Auclair D, Zhang Y, Dogan A, Bolli N, Papaemmanuil E, Anderson KC, Moreau P, Avet-Loiseau H, Munshi NC, Keats JJ, Campbell PJ, Morgan GJ et al. (2020)
Revealing the impact of structural variants in multiple myeloma
Blood Cancer Discov, 1 (3), 258-273
DOI 10.1158/2643-3230.BCD-20-0132, PubMed 33392515

Yang R, Elsaadi S, Misund K, Abdollahi P, Vandsemb EN, Moen SH, Kusnierczyk A, Slupphaug G, Standal T, Waage A, Slørdahl TS, Rø TB, Rustad E, Sundan A, Hay C, Cooper Z, Schuller AG, Woessner R, Borodovsky A, Menu E, Børset M, Sponaas AM (2020)
Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade
J Immunother Cancer, 8 (1)
DOI 10.1136/jitc-2020-000610, PubMed 32409420

Yellapantula V, Hultcrantz M, Rustad EH, Wasserman E, Londono D, Cimera R, Ciardiello A, Landau H, Akhlaghi T, Mailankody S, Patel M, Medina-Martinez JS, Ossa JEA, Levine MF, Bolli N, Maura F, Dogan A, Papaemmanuil E, Zhang Y, Landgren O (2020)
Correction: Comprehensive detection of recurring genomic abnormalities: a targeted sequencing approach for multiple myeloma
Blood Cancer J, 10 (1), 11
DOI 10.1038/s41408-020-0279-4, PubMed 32001687

Ziccheddu B, Biancon G, Bagnoli F, De Philippis C, Maura F, Rustad EH, Dugo M, Devecchi A, De Cecco L, Sensi M, Terragna C, Martello M, Bagratuni T, Kastritis E, Dimopoulos MA, Cavo M, Carniti C, Montefusco V, Corradini P, Bolli N (2020)
Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma
Blood Adv, 4 (5), 830-844
DOI 10.1182/bloodadvances.2019000779, PubMed 32126144

Publications 2019

Landgren O, Hofmann JN, McShane CM, Santo L, Hultcrantz M, Korde N, Mailankody S, Kazandjian D, Murata K, Thoren K, Ramanathan L, Dogan A, Rustad E, Lu SX, Akhlaghi T, Kristinsson SY, Björkholm M, Devlin S, Purdue MP, Pfeiffer RM, Turesson I (2019)
Association of Immune Marker Changes With Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma
JAMA Oncol, 5 (9), 1293-1301
DOI 10.1001/jamaoncol.2019.1568, PubMed 31318385

Maura F, Rustad EH, Yellapantula V, Łuksza M, Hoyos D, Maclachlan KH, Diamond BT, Greenbaum BD, Morgan G, Lesokhin A, Papaemmanuil E, Landgren O (2019)
Role of AID in the temporal pattern of acquisition of driver mutations in multiple myeloma
Leukemia, 34 (5), 1476-1480
DOI 10.1038/s41375-019-0689-0, PubMed 31836853

Rustad EH, Hultcrantz M, Yellapantula VD, Akhlaghi T, Ho C, Arcila ME, Roshal M, Patel A, Chen D, Devlin SM, Jacobsen A, Huang Y, Miller JE, Papaemmanuil E, Landgren O (2019)
Baseline identification of clonal V(D)J sequences for DNA-based minimal residual disease detection in multiple myeloma
PLoS One, 14 (3), e0211600
DOI 10.1371/journal.pone.0211600, PubMed 30901326

Rustad EH, Misund K, Bernard E, Coward E, Yellapantula VD, Hultcrantz M, Ho C, Kazandjian D, Korde N, Mailankody S, Keats JJ, Akhlaghi T, Viny AD, Mayman DJ, Carroll K, Patel M, Famulare CA, Op Bruinink DH, Hutt K, Jacobsen A, Huang Y, Miller JE, Maura F, Papaemmanuil E, Waage A et al. (2019)
Stability and uniqueness of clonal immunoglobulin CDR3 sequences for MRD tracking in multiple myeloma
Am J Hematol, 94 (12), 1364-1373
DOI 10.1002/ajh.25641, PubMed 31571261

Yellapantula V, Hultcrantz M, Rustad EH, Wasserman E, Londono D, Cimera R, Ciardiello A, Landau H, Akhlaghi T, Mailankody S, Patel M, Medina-Martinez JS, Arango Ossa JE, Levine MF, Bolli N, Maura F, Dogan A, Papaemmanuil E, Zhang Y, Landgren O (2019)
Comprehensive detection of recurring genomic abnormalities: a targeted sequencing approach for multiple myeloma
Blood Cancer J, 9 (12), 101
DOI 10.1038/s41408-019-0264-y, PubMed 31827071

Publications 2018

Sponaas AM, Yang R, Rustad EH, Standal T, Thoresen AS, Dao Vo C, Waage A, Slørdahl TS, Børset M, Sundan A (2018)
PD1 is expressed on exhausted T cells as well as virus specific memory CD8+ T cells in the bone marrow of myeloma patients
Oncotarget, 9 (62), 32024-32035
DOI 10.18632/oncotarget.25882, PubMed 30174794

Publications 2017

Rustad EH, Coward E, Skytøen ER, Misund K, Holien T, Standal T, Børset M, Beisvag V, Myklebost O, Meza-Zepeda LA, Dai HY, Sundan A, Waage A (2017)
Monitoring multiple myeloma by quantification of recurrent mutations in serum
Haematologica, 102 (7), 1266-1272
DOI 10.3324/haematol.2016.160564, PubMed 28385781

Publications 2015

Rustad EH, Dai HY, Hov H, Coward E, Beisvag V, Myklebost O, Hovig E, Nakken S, Vodák D, Meza-Zepeda LA, Sandvik AK, Wader KF, Misund K, Sundan A, Aarset H, Waage A (2015)
BRAF V600E mutation in early-stage multiple myeloma: good response to broad acting drugs and no relation to prognosis
Blood Cancer J, 5, e299
DOI 10.1038/bcj.2015.24, PubMed 25794135

Publications 2009

Omsjoe EH, Stien A, Irvine J, Albon SD, Dahl E, Thoresen SI, Rustad E, Ropstad E (2009)
Evaluating capture stress and its effects on reproductive success in Svalbard reindeer
Can. J. Zool., 87 (1), 73-85
DOI 10.1139/Z08-139